New Delhi, Mar 19 (PTI) Sun Pharmaceutical Industries Ltd on Tuesday said the Australian Therapeutic Goods Administration has granted regulatory approval for Winlevi cream indicated for the topical treatment of acne.

The approval is for Winlevi (clascoterone cream 1 per cent), which is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older, the company said in a statement.

Also Read | Martyrs’ Day Dates in India: Bhagat Singh Death Anniversary, Mahatma Gandhi Punyatithi and List of Other Recognised Shaheed Diwas Dates in the Country.

Sun Pharma received the exclusive right to develop and commercialise Winlevi in the US, Japan, Australia, New Zealand, Brazil, Mexico, and Russia from Cosmo, it added.

"Winlevi is an exciting addition to our expanding dermatology portfolio of innovative medicines in Australia. Winlevi's novel mechanism of action will be a welcome addition to the physician's toolkit while treating acne," Hellen de Kloet, Business Head, Western Europe, Australia and New Zealand, Sun Pharma, said.

Also Read | Bihar Day 2024 Date and Significance: Know About Bihar Sthapana Diwas History and Celebrations That Take Place To Honour the Formation of the State.

The company said Winlevi will be available in Australia this June.

"This is another achievement in the mission of Cosmo and Sun Pharma to improve the lives of patients affected by skin conditions," Cosmo President of the Dermatology Division Diana Harbort said.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)